PMID- 16213318
OWN - NLM
STAT- MEDLINE
DCOM- 20060131
LR  - 20131121
IS  - 0041-1345 (Print)
IS  - 0041-1345 (Linking)
VI  - 37
IP  - 7
DP  - 2005 Sep
TI  - Is HLA-DR6 a protective factor against posttransplantation diabetes mellitus?
PG  - 3098-100
AB  - BACKGROUND: Posttransplant diabetes mellitus (PTDM) has several pre- and 
      posttransplant risk factors. METHODS: The incidence and risk factors of PTDM were 
      retrospectively evaluated in 2117 kidney allograft recipients from June 1984 to 
      March 2004. Type and dosage of immunosuppressive agents, pretransplant weight and 
      human leukocyte antigen (HLA) phenotypes in PTDM patients were compared with 61 
      matched controls. RESULTS: Sixty-one cases (2.8%) developed PTDM requiring 
      insulin or oral hypoglycemic therapy, out of which 47.5% were men and 52.5% were 
      women, although only 35% of our overall recipients are women. Onset occurred at a 
      mean of 489 days following transplantation. Patients receiving more than 15 mg/d 
      prednisolone developed PTDM more often than those on less than 15 mg/d (P = 
      .000). Similarly PTDM was more frequent among patients who received more than 300 
      mg/d cyclosporine compared with those on less than 300 mg/d (P = .015). Mean 
      weight in PTDM cases and controls was 65 +/- 13.4 kg and 57 +/- 13.6 kg, 
      respectively (P = .005). HLA-DR6 was observed in 12.2% of nonaffected subjects 
      but in none of the PTDM group (P = .002). Conversely, HLA-DR8 was seen only in 
      PTDM patients (P = .012). In addition HLA-A26 was more common among PTDM patients 
      (P = .02) and HLA-DR52 more frequent in nonaffected subjects (P = .025). 
      CONCLUSION: Our findings suggest that female sex, dosages of prednisolone and 
      cyclosporine, pretransplant weight, and genetic factors are associated with an 
      increased risk of PTDM. The rate of PTDM appeared to be independent of weight 
      gain in the first year posttransplant. Protection against PTDM may be afforded by 
      HLA-DR6 and possibly HLA-DR52. Conversely and higher incidence of diabetes has 
      been associated with HLA-DR8 and HLA-A26.
FAU - Nafar, M
AU  - Nafar M
AD  - Urology/Nephrology Research Center, Shaheed Labbafinejad Medical Center, Shaheed 
      Beheshti University of Medical Sciences, Tehran, Iran. nafarm@hbi.or.ir
FAU - Pour-Reza-Gholi, F
AU  - Pour-Reza-Gholi F
FAU - Amouzegar, A
AU  - Amouzegar A
FAU - Einollahi, B
AU  - Einollahi B
FAU - Firouzan, A
AU  - Firouzan A
FAU - Hemati, K
AU  - Hemati K
FAU - Amjadi, H
AU  - Amjadi H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (HLA-DR6 Antigen)
RN  - 9PHQ9Y1OLM (Prednisolone)
SB  - IM
MH  - Body Weight
MH  - Diabetes Mellitus/epidemiology/immunology/*prevention & control
MH  - Female
MH  - HLA-DR6 Antigen/*blood
MH  - Humans
MH  - Incidence
MH  - Kidney Transplantation/*adverse effects/immunology
MH  - Male
MH  - Medical Records
MH  - Postoperative Complications/epidemiology/immunology/prevention & control
MH  - Prednisolone/adverse effects
MH  - Retrospective Studies
MH  - Risk Factors
EDAT- 2005/10/11 09:00
MHDA- 2006/02/01 09:00
CRDT- 2005/10/11 09:00
PHST- 2005/10/11 09:00 [pubmed]
PHST- 2006/02/01 09:00 [medline]
PHST- 2005/10/11 09:00 [entrez]
AID - S0041-1345(05)00838-9 [pii]
AID - 10.1016/j.transproceed.2005.08.008 [doi]
PST - ppublish
SO  - Transplant Proc. 2005 Sep;37(7):3098-100. doi: 
      10.1016/j.transproceed.2005.08.008.